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Abstract Using simulated viral load data for a given maraviroc monotherapy
study design, the feasibility of different algorithms to perform parameter estimation
for a pharmacokinetic-pharmacodynamic-viral dynamics (PKPD-VD) model was
assessed. The assessed algorithms are the ﬁrst-order conditional estimation method
with interaction (FOCEI) implemented in NONMEM VI and the SAEM algorithm
implemented in MONOLIX version 2.4. Simulated data were also used to test if an
effect compartment and/or a lag time could be distinguished to describe an observed
delay in onset of viral inhibition using SAEM. The preferred model was then used to
describe the observed maraviroc monotherapy plasma concentration and viral load
data using SAEM. In this last step, three modelling approaches were compared; (i)
sequential PKPD-VD with ﬁxed individual Empirical Bayesian Estimates (EBE) for
PK, (ii) sequential PKPD-VD with ﬁxed population PK parameters and including
concentrations, and (iii) simultaneous PKPD-VD. Using FOCEI, many convergence
problems (56%) were experienced with ﬁtting the sequential PKPD-VD model to
the simulated data. For the sequential modelling approach, SAEM (with default
settings) took less time to generate population and individual estimates including
diagnostics than with FOCEI without diagnostics. For the given maraviroc mono-
therapy sampling design, it was difﬁcult to separate the viral dynamics system delay
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DOI 10.1007/s10928-010-9175-zfrom a pharmacokinetic distributional delay or delay due to receptor binding and
subsequent cellular signalling. The preferred model included a viral load lag time
without inter-individual variability. Parameter estimates from the SAEM analysis of
observed data were comparable among the three modelling approaches. For the
sequential methods, computation time is approximately 25% less when ﬁxing
individual EBE of PK parameters with omission of the concentration data compared
with ﬁxed population PK parameters and retention of concentration data in the
PD-VD estimation step. Computation times were similar for the sequential method
with ﬁxed population PK parameters and the simultaneous PKPD-VD modelling
approach. The current analysis demonstrated that the SAEM algorithm in
MONOLIX is useful for ﬁtting complex mechanistic models requiring multiple
differential equations. The SAEM algorithm allowed simultaneous estimation of
PKPD and viral dynamics parameters, as well as investigation of different model
sub-components during the model building process. This was not possible with the
FOCEI method (NONMEM version VI or below). SAEM provides a more feasible
alternative to FOCEI when facing lengthy computation times and convergence
problems with complex models.
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Introduction
Maraviroc (UK-427,857) is a reversible and selective antagonist of the human
chemokine CCR5 receptor [1]. It has been approved for use in combination with
other antiretroviral agents for the treatment of subjects infected with CCR5-tropic
human immunodeﬁciency virus type 1 (HIV-1). Two short-term 10 days mono-
therapy treatment phase 2a studies (A4001007 and A4001015) were performed in
asymptomatic CCR5-tropic HIV-1 infected subjects [2]. The maraviroc doses
ranged from 25 mg once daily (QD) to 300 mg twice daily (BID). The mean HIV-1
viral load declined in a dose-dependent fashion with up to 1.6 log10 RNA
copies ml
-1 achieved (at day 11) with 300 mg BID [2].
Mathematical models have been widely used to describe the dynamics and
interaction of target CD4
? cells, actively, latently, persistently and defectively
infected cells and plasma virus in HIV-1 infected asymptomatic subjects after
initiation of antiretroviral therapy [3–5]. These models employ sets of differential
equations to describe the viral dynamics. The maraviroc monotherapy data have
previously been analyzed in a two-stage approach by ﬁtting a pharmacokinetic-
pharmacodynamic-viral dynamics (PKPD-VD) model [6, 7] using nonlinear mixed-
effects modelling for estimation of ﬁxed effects, inter-individual (IIV) and residual
variability implemented in the NONMEM software [8]. NONMEM estimation
methods include a ﬁrst-order method (FO) and ﬁrst-order conditional estimation
(FOCE) method, both of which involve linearization of the regression function with
respect to the random effects [9–12]. Some of the practical drawbacks and/or
limitations when performing PKPD-VD parameter estimations with the FOCE
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are:
(i) very long computation times;
(ii) convergence problems resulting from numerical difﬁculties in optimizing the
linearized likelihood;
(iii) model instability necessitating a two-stage approach (PK modelling followed
by PKPD-VD modelling) and limitations in numbers of parameters that can
be estimated;
(iv) difﬁculties with models that have change points such as lag times.
These factors make it very difﬁcult to develop these complex PKPD models or to
perform simultaneous PKPD-VD modelling with the FOCEI method.
MONOLIX [13] implements a stochastic approximation (SA) of the standard
expectation maximization (EM) (=SAEM) algorithm for nonlinear mixed-effects
models without approximations. The SAEM algorithm replaces the usual estimation
step of EM by a stochastic procedure which has been shown to be very efﬁcient with
improved convergence toward the maximum likelihood (ML) estimates [14]. SAEM
(as well as other EM-type algorithms) performs ML estimation without any
approximation of the statistical model. Then ‘‘optimal’’ statistical properties
(consistency and minimum variance of the estimate) are expected with SAEM. In
addition, implementation of SAEM in MONOLIX has been optimized; settings of
the Markov Chain Monte Carlo (MCMC) used for the simulation step have been
carefully deﬁned (combination of several transition kernels, optimal acceptance
rate, etc.), and a simulated annealing procedure accelerates the convergence of the
algorithm toward the solution. A review of population analysis methods and
software using examples for complex PK and PD methods concludes that EM
methods (performed by S-ADAPT, PDx-MCPEM and MONOLIX) have greater
stability in analyzing complex PKPD models and can provide accurate results with
sparse and rich data [12].
The objectives of the present analysis were to assess the SAEM functionality
implemented in MONOLIX for complex mechanistic models in the application of
population PKPD-VD modelling of maraviroc monotherapy PK and viral load data.
Three key questions are addressed (Fig. 1):
(i) The feasibility of the FOCEI method (implemented in NONMEM VI) and the
SAEM algorithm (implemented in MONOLIX) to perform parameter estima-
tion for a PKPD-VD population model using simulated data;
(ii) Determination of a preferred model using SAEM in looking at a lag time and
an effect site delay model (ke0 model) using simulated data;
(iii) Comparison of parameter estimates with sequential (two-stage) versus
simultaneous modelling approaches using SAEM and observed data from
maraviroc monotherapy studies.
The aim of this paper is thus not to directly compare parameter estimates from
SAEM and FOCEI, but to explore SAEM as a tool that may allow efﬁcient/stable
estimates of PKPD and VD parameters within a nonlinear mixed effects framework
with two levels of random variability.
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Data
An analysis of the data from two randomized, placebo-controlled, phase 2a
monotherapy studies (A4001007 and A4001015) has been performed; rich plasma
maraviroc concentrations (1,250 samples) and viral load data (1,169 observations)
were available from 63 asymptomatic CCR5-tropic HIV-1 infected patients.
Approval from local ethics committees was obtained and written informed consent
was obtained from all subjects. These studies are described in more detail elsewhere
[2].
Patients were randomly assigned to the following treatment groups: maraviroc
25 mg QD, 50, 100 or 300 mg BID, or placebo under fasted conditions in study
A4001007; maraviroc 150 mg BID (fed and fasted), 100 or 300 mg QD, or placebo
under fasted conditions in study A4001015. In both studies, patients received
treatment for 10 days and were followed up for 30 days after the last dose. The
current analysis included data arising from patients who were assigned to one of the
maraviroc treatment arms and excluded placebo data.
Blood samples were collected for determination of maraviroc plasma concen-
trations pre-morning dosing on days 1–10, and at speciﬁed times up to at least 24 h
post dose on day 10. In A4001007, several additional samples up to 12 h post-
morning dose on day 1, as well as 48, 72 and 120 h post dose on day 10 were
collected.
Plasma samples were analysed by a centralized laboratory (Maxxam Analytics
Inc, Mississauga ON, Canada) to determine maraviroc concentrations. The
analytical procedure employed solid phase extraction of the analyte and internal
standard with separation by high-performance liquid chromatography followed by
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Fig. 1 Schematic representation of the analysis plan. Simulation model = PKPD-VD with LagE and
ke0, IIV on IC50 and VD parameters (RR0, b and d2)
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The same analytical method was used in both studies. The lower limit of
quantiﬁcation was 0.5 ng ml
-1. Plasma HIV-1 RNA viral load were assessed at
screening, randomization, and on days 1–13, 15, 19, 22, 25 and 40 using the Roche
Amplicor v1.5 RT-PCR assay (Roche Diagnostics). Baseline viral load was
computed as the mean of three log10 transformed predose values.
PKPD-viral dynamics model
The PKPD-VD model has 3 components [7]:
PK model
Abasic2-compartmentdispositionmodel(Eqs. 1–3),parameterizedasclearances(total
CL and intercomparmental Q) and volumes (central V2 and peripheral V3), with ﬁrst-
order absorption (ka), an absorption lag time (LagC), food effects on ka and F1 (relative
bioavailability) and an additive residual error model was used to ﬁt the log-transformed
maraviroc concentrations. The individual Empirical Bayesian Estimates (EBE) of PK
parameters were used to predict the drug concentration at the speciﬁc times when viral
loads were measured for the second stage sequential PKPD-VD modelling.
Absorption compartment 1:
dAð1Þ
dt
¼  k12   Að1Þð 1Þ
Central compartment 2:
dAð2Þ
dt
¼ k12   Að1Þþk32   Að3Þ k23   Að2Þ k20   Að2Þ
ð2Þ
Peripheral compartment 3:
dAð3Þ
dt
¼  k32   Að3Þþk23   Að2Þð 3Þ
where k12 = ka,k 20 ¼ CL
V2; k23 ¼
Q
V2; k32 ¼
Q
V3: ka is the absorption rate constant;
CL is the clearance; Q is the intercompartmental clearance; V2 is the central volume;
V3 is the peripheral volume.
PD model
Based on the known mechanism of action of maraviroc, the effect was modelled
using an inhibitory Emax model acting on the infection rate of the virus and target
CD4
? cells. An area of interest, in modelling HIV-1 viral load changes in response
to treatment, is exploration of the observed time delay component of viral load
response to drug treatment.
After the start of antiretroviral therapy, a delay (1–2 days) in the effect on viral
load is usually observed regardless of the antiretroviral agent (irrelevant of its PK
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time required for drug absorption, disposition, interaction with the target receptor/
enzyme, activation of subsequent cellular or intra-cellular pathways, as well as the
clearance of free virus particles and the death of infected cells. Different modelling
approaches can be used to describe such a delay, e.g.
(i) introduction of a lag time between PK and PD;
(ii) the use of an effect compartment model (Eq. 4) to describe the time lag
between plasma drug concentration and drug effect with an equilibration half
time parameter (ke0)[ 19];
Effect compartment 4:
dAð4Þ
dt
¼ ke0  
Að2Þ
V2
  Að4Þ

ð4Þ
(iii) an onset/offset model where different rate constants are allowed for the onset
and offset of response.
All of the above approaches increase the complexity of the PKPD-VD model and
make estimation with the FOCEI method more difﬁcult. This offered a further
opportunity for testing the functionality of SAEM (implemented in MONOLIX).
In previous analyses of the maraviroc monotherapy data using FOCEI
(unpublished data), the delay in onset and offset of viral inhibition was modelled
with a lag time (LagE) and ke0. This allowed for the shift of the PK proﬁle from the
onset and offset of viral inhibition.
Viral dynamics model
Details of the VD model are described elsewhere [3–7]. Brieﬂy, the dynamics
and interaction of target CD4
? cells, actively infected CD4
? cells, latently
infected CD4
? cells and viruses in HIV-1 infected asymptomatic patients after
initiation of antiretroviral therapy were modelled with a set of differential
equations (Eqs. 5–9a, b).
Target cell (activated CD4
? cells):
dT
dt
¼ b   d1   T  ð 1   INHÞ i   V   T ð5Þ
Actively infected cell (short-lived):
dA
dt
¼ f1  ð 1   INHÞ i   V   T   d2   A þ a   L ð6Þ
Latently infected resting cells (long-lived):
dL
dt
¼ f2  ð 1   INHÞ i   V   T   d3   L   a   L ð7Þ
Infectious virus (copies HIV-1 RNA):
dV
dt
¼ p   A   c   V ð8Þ
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(i) driven by central compartment concentration
INH ¼
Að2Þ
V2
IC50 þ
Að2Þ
V2
 ð9aÞ
(ii) driven by effect compartment concentration
INH ¼
Að4Þ
IC50 þ Að4Þ ðÞ
ð9bÞ
where b is the birth rate constant of healthy target CD4
? cells (T); d1 is the death
rate constant of T cells; i is the infection rate of T cells; V is the number of virus
particles; INH is the viral inhibition fraction driven by (central or effect
compartment) maraviroc concentration with an inhibitory Emax model where
maximal inhibition is ﬁxed to 1; f1 is the fraction of healthy T cells which become
short-lived actively infected T cells (A); d2 is the death rate constant of short-lived
actively infected T cells; f2 = (1 - f1) is the fraction of healthy T cells which
become latently infected resting cells (L); d3 is the death rate constant of latently
infected resting cells; a is the reactivation rate constant of latently infected resting
cells; p is the viral production rate of short-lived actively infected T cells; c is the
death rate constant of virus. The persistently and defectively infected cells with very
long half-lives were excluded in the current analysis as they are not relevant to
short-term (10 day) data.
The in vivo maraviroc IC50 and VD parameters (basic reproductive ratio (RR0),
b and d2) were estimated. All remaining viral dynamic inputs were ﬁxed to values
based on literature ranges [6, Table 1].
RR0 is a derived model parameter computed as the ratio of the birth rate
constants to the death rate constants (Eq. 10). RR0 gives the average number of
offspring generated by a single virus particle in the absence of constraints [4]. When
RR0 in the presence of an inhibitor is below 1, the system theoretically goes
to extinction. When RR0 is above 1, the system adjusts to the inhibition and
re-equilibrates to a new steady state.
RR0 ¼
b
d1
  i  
p
c
 
f1
d2
þ
f2   a
d2  ð d3 þ aÞ

ð10Þ
The reproduction minimum inhibitory concentration (RMIC) is deﬁned as the
concentration of an antiretroviral compound that decreases RR0 to below the break
point of 1 which results in eradication of the disease [20]. Given that RR0 and IC50
are highly correlated during the estimation process, RMIC was computed (Eq. 11)
to make more appropriate comparisons of these key parameter estimates obtained
from different models or algorithms in the current analysis.
RMIC ¼ð RR0   1Þ IC50 ð11Þ
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The current analyses were performed using:
(i) A nonlinear mixed-effects modelling methodology as implemented in the
NONMEM software system, version VI level 1.2 [8] (patched with updated
subroutines according to instructions provided from GloboMax/ICON on 30
August 2007). NM-TRAN subroutines version IV level 1.1, and the PREDPP
model library (ADVAN6 TOL = 5), version V level 1.0 utilizing Intel-based
PC Workstations (Pentium 4 Intel
 Xeon
 CPU Processor @ 3.06 or
3.20 GHz) running Red Hat Linux (3.4.6-8) operating system (GRID system)
and GNU Fortran compiler (GCC 3.4.6 20060404) were used. Parameter
estimation was performed using the FOCEI method. ADVAN6 TOL = 5 was
chosen to be the default setting because previous experiences with NONMEM
had shown that none of the other PREDPP model library or TOL settings
improved computation time or convergence.
(ii) The SAEM algorithm as implemented in MONOLIX version 2.4 via
MATLAB version 7.5.0 on a Microsoft Windows XP operating system
installed on a ThinkPad T61 with Intel
 Core
TM Duo CPU T7300 processors
@ 2.00 GHz and 1.96 GB of RAM.
Analysis plan
Part 1: assessing ﬁtting feasibility of the FOCEI and SAEM algorithms
with simulated data
The ﬁrst question to be addressed was the feasibility of the FOCEI and SAEM
algorithms to perform parameter estimation for the PKPD-VD model. Simulation of
Table 1 Selection of the preferred model using SAEM given the maraviroc monotherapy study design
(n = 50)
Model With inter-individual variability
on LagE and/or ke0?
Number of times selected
as preferred model [%]
No lag time No 0 [0]
No effect compartment
Lag time only No 48 [96]
Lag time only Yes 4 [8]
a
Effect compartment only No 0 [0]
Effect compartment only Yes 0 [0]
With lag time and effect compartment No 6 [12]
b
With lag time and effect compartment Yes 0 [0]
a Only 2 coincided with the 48 runs from the lag time only model without x[LagE]
b All 6 coincided with the 48 runs from the lag time only model without x[LagE]
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study designs to the maraviroc monotherapy studies (subject numbers, doses and
observations). Parameter estimates from a previous PKPD-VD analysis of the data
using FOCEI including IIV (on IC50, RR0, b and d2) and residual error but not
including parameter uncertainty (unpublished data, details in PKPD-Viral Dynamics
Model section) were used.
The viral inhibition was driven by the predicted PK proﬁle based on the
population PK parameter estimates excluding IIV and residual error. This was done
to eliminate the potential impact of maraviroc PK on the VD parameter estimation.
The simulated concentration and viral load data were then ﬁtted separately using
FOCEI and SAEM, with the true parameter values as the initial conditions. Fitting
feasibility was assessed by the number of runs that terminated with successful
minimization and other termination messages in NONMEM VI, as well as the
precision of parameter estimates (compared with the ‘‘true’’ values used in
simulation) obtained from FOCEI and SAEM.
If a run using FOCEI terminated due to ‘‘rounding errors’’, one more attempt/
run was made by using the ﬁnal parameter estimates as the initial parameter
estimates. If the second attempt minimized successfully, the run was classiﬁed
as successful; otherwise it was classiﬁed as run terminated with ‘‘rounding
errors’’.
Part 2: determination of the preferred model using simulated data with SAEM
Since different modelling approaches can be used to describe the delay in onset and
offset of viral inhibition, another issue was to determine if SAEM could be used to
estimate parameters describing the delay for a given maraviroc monotherapy study
design with simulated data. While the simulation PD model had both a lag time
(LagE) and an effect compartment model (ke0) describing the delay in onset and
offset of viral inhibition, the 50 simulated viral load datasets were ﬁtted to different
PD models using SAEM, i.e. inclusion/exclusion of LagE and an effect compart-
ment, as well as with/without IIV on LagE and ke0.
The preferred model was selected based on the precision of parameter estimates,
standard error of population parameters, correlation of estimates, log-likelihood (by
Monte-Carlo Importance Sampling), information criteria such as Akaike informa-
tion criterion (AIC) and Bayesian information criterion (BIC).
The 50 simulated viral load datasets were also ﬁtted to the preferred model
using FOCEI in order to determine if numerical difﬁculties occur with the less
complex model. Bias and imprecision for model parameters were measured by the
mean prediction error and the root mean squared prediction error [21],
respectively. In addition, stability of the preferred model with the FOCEI and
SAEM algorithms was assessed using Perl-speaks-NONMEM (PsN version 2.3.0)
[22] with the execute function. PsN enables automatic retrial of runs using slightly
perturbed initial estimates. The minimum and maximum retries were set to 2 and
5, respectively.
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and simultaneous modelling approaches using SAEM
Finally, the observed maraviroc concentration and viral load data were ﬁtted with
the preferred model (deﬁned in Part 2) using SAEM and 3 different modelling
approaches:
(i) Sequential PK and PD-VD, where PK parameters were estimated from the PK
data alone, then the PD-VD parameters were estimated based on the PD data
and the ﬁxed individual EBE of PK parameters. PK data were omitted in this
PD-VD parameter estimation step;
(ii) Sequential PK and PD-VD with PK parameters ﬁxed to population estimates
obtained from the separate PK analysis as described in (i). The PD-VD
parameters were estimated conditionally on the ﬁtted PK model and also the
PK concentration data were retained in this sequence;
(iii) Simultaneous PKPD-VD, where PK and PD-VD parameters were estimated
simultaneously in the presence of both concentration and viral load data.
The overall aim was to assess the performance of SAEM for parameter
estimation in the presence/absence of concentrations when coupling/uncoupling the
PK and PD-VD components of the PKPD-VD model.
Results
Part 1: assessing ﬁtting feasibility of the FOCEI and SAEM algorithms
When analyzing the 50 simulated viral load data sets with FOCEI, 22 runs
experienced numerical difﬁculties, of which 18 runs did not execute a single
iteration. Six runs terminated with ‘‘rounding errors’’ (on the second attempt). Only
22 runs terminated with ‘‘minimization successful’’, of which half failed to run a
covariance step. Of the 22 successful runs, 8 had unreasonable estimates of ke0
(4 runs with 131–171 fold increases, 2 runs with 11.7 and 1,621 fold increases
respectively, 2 runs with 2.7 and 5 fold decreases) and/or LagE (2 runs with two to
three fold decreases). For the 2 runs with unreasonable estimates of both ke0 and
LagE, ke0 (0.564 and 1.07 day
-1) was 2.7 and 5.1 fold lower, while LagE (0.368 and
0.483 days) was[twofold lower than the true parameter values (ke0 = 2.86 day
-1,
LagE = 1.13 days).
Parameter estimates were obtained for all 50 simulated data sets using SAEM.
Six runs had estimates of ke0 (4 runs with 2–2.65 fold lower estimates), RR0 (1 run
with 5.5 fold higher estimate) and/or IC50 (2 runs with 2.2 and 47 fold higher
estimates) inconsistent with the values used for simulation. For the run with both
unreasonable estimates of RR0 and IC50,I C 50 (418 ng ml
-1) was 47-fold higher
than the ‘‘true’’ parameter value of 8.66 ng ml
-1. For both the FOCEI and SAEM
algorithms, parameter estimation of ke0 was troublesome.
The computation time for the 22 successful runs with FOCEI ranged from 1.75 to
192.8 h (median * 3 h) without any post processing for diagnostics. With SAEM,
50 J Pharmacokinet Pharmacodyn (2011) 38:41–61
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using the default settings (number of simulation samples: visual predictive checks
(VPC) = 100, normalized prediction distribution errors (NPDE) = 500, Monte-
Carlo size used for estimating the log-likelihood (LLP) = 10,000).
Part 2: determination of the preferred model using simulated data with SAEM
A general ﬁnding when ﬁtting the 50 simulated viral load data sets using SAEM
with different PD-VD models was the difﬁculty in determining both ke0 and LagE
parameters given the viral load sampling times. The preferred model was the lag
time model without an effect compartment and without IIV on LagE. This model
described 48 (96%) simulated data sets the best (Table 1) based on the criteria listed
in methods. The run time for the PD-VD estimation step ranged from 1.5 to 2.5 h.
When analyzing the 50 simulated viral load data sets with FOCEI using the
preferred model, 21 runs experienced numerical difﬁculties, of which 15 runs did
not execute a single iteration; 5 runs terminated with ‘‘rounding errors’’ (on the
second attempt). Twenty-four runs terminated with ‘‘minimization successful’’, of
which 4 failed to run a covariance step.
Distribution plots of the parameter estimates obtained from the successful runs
for SAEM and FOCEI together with the true values used for simulation are shown
in Figs. 2 and 3, respectively. In general, LagE was overestimated with both SAEM
and FOCEI largely due to the exclusion of the effect compartment. Parameter
estimates obtained from SAEM were more randomly spread around their true
values, particularly for the random effects parameter estimates.
With a minimum of 2 and maximum of 5 retries of random changes in starting
estimates using PsN, 31 of the 50 simulated data sets had at least one run terminated
with ‘‘minimization successful’’. Ten out of the 31 simulated data sets were also
analyzed using SAEM with the initial estimates perturbed exactly as in PsN. In
general, the minimum to maximum variation of the ﬁxed effects parameter
estimates obtained from the 2 to 5 retries was less than twofold. A bigger variation
was seen in the random effects estimates using FOCEI; 3 out of 31 had a 3–3.5 fold
variation and 1 out of 31 had a 13 fold variation in IIV of d2.
The preferred model with LagE but without IIV on LagE was taken forward for
Part 3 analysis.
Part 3: comparison of parameter estimates obtained from sequential
and simultaneous modelling approaches using SAEM
The PK parameter estimates obtained from sequential and simultaneous PKPD-VD
modelling approaches using SAEM are presented in Table 2. Food effects on ka and
F1 were modelled as fractional changes with fasted status as the reference group.
Due to the limited amount of data where maraviroc was administered with food and
the potential distortion of the PK model by a mis-speciﬁed PD model, the impact of
the food effect on ka and F1 were very different between the sequential and
simultaneous PKPD modelling approaches. However, the relative standard errors
suggest that the food effect on ka, particularly for the simultaneous PKPD analyses,
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associated IIV were similar between the sequential and simultaneous PKPD
modelling approaches with small relative standard error (RSE).
The PD-VD model parameter estimates, along with the computed RMIC,
obtained from the sequential and simultaneous PKPD approaches are presented in
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123Table 3. The computed RMIC, the VD parameters and their associated IIV were
comparable across the 3 different modelling approaches for the given drug effect
(PD) model. For the sequential method with ﬁxed individual EBE PK (omission of
PK data in the PD-VD parameter estimation step), the computation time was
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123approximately 25% shorter than the sequential method with ﬁxed population PK
parameters (PK data retained in the PD-VD parameter estimation step). Interest-
ingly, no computation time was saved by ﬁxing population PK parameters in the
sequential method compared with the simultaneous PKPD-VD modelling approach.
Run times ranged from 10 to 16 h including diagnostics using default settings for
both. The visual predictive checks for the plasma maraviroc concentrations and viral
loads obtained from the ﬁnal PKPD-VD model using a simultaneous PKPD
modelling approach are shown in Figs. 4 and 5, respectively. The goodness-of-ﬁt
plots are presented in Fig. 6.
Discussion
NONMEM is a widely used tool for population PKPD modelling. However, as
shown in the current analysis, when complex semi-mechanistic models involving
the use of a differential equation solver are necessary, the FOCEI method
Table 2 Comparison of PK parameter estimates obtained from sequential and simultaneous PKPD
modeling approaches with SAEM
Deﬁnition Parameter PK alone (PK estimation
step of the two-stage
approach)
Simultaneous PKPD
Population
estimate
RSE
(%)
Population
estimate
RSE
(%)
Total clearance CL (l day
-1) 5500 6 5180 6
Central volume V2 (l) 274 12 349 10
Intercompartmental clearance Q (l day
-1) 1140 8 1290 8
Peripheral volume V3 (l) 1040 9 1130 9
Absorption rate constant ka (day
-1) 8.11 10 9.36 10
Food effect on ka Food on ka -0.755
a 36 -0.141
c 222
Relative bioavailability F1 1 FIX – 1 FIX –
Food effect on F1 Food on F1 -0.244
b 45 -0.476
d 14
Absorption lag time LagC (days) 0.0211 10 0.0178 13
IIV on CL x[CL] (%) 46.6 9 46.9 9
IIV on V2 x[V2] (%) 60.6 16 55.5 15
IIV on Q x[Q] (%) 35.1 20 47.2 15
IIV on V3 x[V3] (%) 40.0 22 51.4 15
IIV on ka x[ka] (%) 64.1 11 69.9 11
IIV on LagC x[LagC] (%) 39.0 26 60.2 20
Residual error Additive error (%) 45.4 2 44.6 2
a P value = 0.0049
b P value = 0.028
c P value = 0.65
d P value\0.0001
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123implemented in NONMEM (versions up to VI) often experiences convergence
problems resulting from numerical difﬁculties in performing parameter estimates. In
addition, the long computation time and the model instability limit the use of FOCEI
for model building as with this example of a combined PKPD-VD model. As
modelling and simulation activities move towards more complex mechanistic
models it becomes necessary to investigate more practical tools, with better
estimation methods such as SAEM. This method was not available in NONMEM
versions VI or earlier. Bauer et al. [12] have published a review benchmarking
commonly available population analysis tools. This review includes a summary of
the statistical theory behind the methods and testing of 4 models including one
example of a more complex PKPD model and differential equations requiring
numerical integration. At that time MONOLIX 2.4 was not available. However they
Table 3 Comparison of PD and VD parameter estimates obtained from sequential and simultaneous
PKPD modeling approaches with SAEM
Deﬁnition Parameter Sequential PKPD
with ﬁxed
individual EBEs
of PK parameters
(omission of PK
data in PD-VD
estimation step)
Sequential PKPD
with ﬁxed
population PK
parameters
(retention of PK
data in PD-VD
estimation step)
Simultaneous
PKPD
Population
estimate
RSE
(%)
Population
estimate
RSE
(%)
Population
estimate
RSE
(%)
Basic reproductive ratio RR0 5.33 10 5.92 11 4.96 9
Birth rate of T cells b [day
-1] 1.22 15 1.18 13 1.36 14
Death rate of T cells d2 [day
-1] 0.797 4 0.755 3 0.841 3
In vivo potency IC50
(ng ml
-1)
8.27 19 6.73 22 8.57 24
Lag time of viral inhibition LagE (days) 1.52 1 1.35 3 1.43 6
IIV of RR0 x[RR0] (%) 78.6 10 79.4 10 64 10
IIV of b x[b] (%) 114 9 103 9 110 9
IIV of d2 x[d2] (%) 29.3 11 20.6 12 19.6 13
IIV of IC50 x[IC50] (%) 137 11 160 10 175 10
Residual error Additive
error (%)
47.9 2 48.1 2 47.9 2
Reproduction minimum
inhibitory concentration
RMIC
(ng ml
-1)
a
35.8 – 33.1 – 33.9 –
Log-likelihood -2 9 log-
likelihood
b
291
c 2367 2390
Akaike information criterion AIC
b 311
c 2387 2440
Bayesian information
criterion
BIC
b 332.5
c 2409 2493
a RMIC = (RR0 - 1) 9 IC50
b Estimation by importance sampling
c Values can not be directly compared with other approaches due to different number of observations
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123conclude that EM methods have an advantage of greater stability in population
analyses of complex PKPD models with reduced bias in assessing sparse and rich
data than FOCE [23].
The SAEM algorithm has previously been used by Lavielle and Mentre ´ [24]t o
perform population PK analysis of a protease inhibitor, saquinavir, with large IIV.
Samson et al. [25] have also successfully applied the SAEM algorithm to describe
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Fig. 4 Visual predictive check for plasma maraviroc concentrations stratiﬁed by treatment arm. Symbols
denote observations. Dashed and solid lines represent median and the 90% prediction intervals
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123the longitudinal decrease in log10 viral load (left censored data) after initiation of
antiretroviral treatments, with a right-truncated Gaussian distribution. In addition to
the ability of performing parameter estimation, the relatively shorter computation
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123times (compared with the FOCEI method) allows exploration of different
components of the PD models as well as exploring different modelling approaches
to assess the impact of PK data on PD parameter estimation, and vice versa.
The ﬁtting feasibility of the FOCEI method (implemented in NONMEM VI) and
the SAEM algorithm (in MONOLIX) were compared in the ﬁrst part of this work
using 50 simulated data sets. In this test FOCEI experienced numerical difﬁculties
with 44% of the data sets. In addition a further 12% of runs ﬁnished with rounding
errors and 22% had a failed covariance step. The SAEM algorithm on the other hand
always produced estimates of PKPD-VD parameters using either a sequential or
simultaneous modelling approach, although in a minority of cases these were not
very likely. Because parameter estimates for ﬁxed effects and variances as well as
standard errors are generated in all runs with SAEM, the feasibility to perform
PKPD-VD parameter estimation was determined by assessing the precision of
parameter estimates as in relative standard error estimates. With FOCEI, more
difﬁculties in estimating both ke0 and LagE (with relatively little information
available from the study design) were experienced. Unlikely parameter estimates for
IC50 and RR0 compared with the simulated model parameters were generated only
occasionally (12%) using SAEM.
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Fig. 6 Basic goodness of ﬁt for the ﬁnal PKPD-VD model using a simultaneous PKPD modeling
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123Using simulated data sets, the current analysis attempted to separate the system
delay from the delay of pharmacological effect using a lag time and an effect
compartment. Unfortunately, for the given maraviroc monotherapy viral load
sampling design, it was difﬁcult to separate the PD lag due to drug effects from a
system delay. Herz et al. [26] developed a mathematical model which incorporated
an intracellular phase of the viral life-cycle to account for the virus production lag.
The authors of that study concluded that plasma viral load data alone do not allow a
clear distinction between the delays of pharmacological action, intracellular delays
and the clearance of free virus during the transition phase. It was also suggested that
frequent clinical measurements for 2 days after initiation of antiretroviral therapies
are required in order to improve parameter estimates. In addition, frequent clinical
measurements after the termination of antiretroviral therapies also provide very
valuable information. For the model parameterization used in the current analysis,
the key to improve the precision of RR0 is the clinical measurement of viral load in
the rebound period upon termination of antiretroviral therapies. Thus it can be
concluded that data or study design limitations rather than the estimation method in
SAEM (in MONOLIX) are an issue in parameter identiﬁcation for lag times.
With the PKPD-VD model with lag time only, the LagE estimate was
approximately 1.5 days. This is consistent with the observed delay in viral load
drop after the initiation and termination of antiviral therapy and an approximate
2 day half-time of the free virus particles and/or virus producing cells [27–29].
For good PKPD modelling practice, one should always examine the correlation
between the PK of a compound and the drug effects (surrogate biomarkers or
clinical measurements), as well as their interactions, i.e. the impact of one on the
other. The current analysis compared parameter estimates obtained from different
modelling approaches using SAEM: sequential methods with ﬁxed individual PK
parameter EBEs; ﬁxed population PK parameters with concentration data; a
simultaneous method. In general, with the maraviroc monotherapy study design and
data, the structural parameters of the PK, PD and VD model components were
comparable across different modelling approaches. Zhang et al. [30] have
demonstrated that PK ﬁts using a simultaneous modelling approach can be quite
sensitive to the PD model, particularly when there was misspeciﬁcation in the PD
model. Interestingly, Zhang et al. [31] also found that with the FOCE method in
NONMEM, the sequential modelling approach saved about 40% of computation
time compared with the simultaneous modelling approach. In the current analysis,
with the SAEM algorithm, no computation time was saved by using the sequential
PKPD modelling approach with ﬁxed population PK parameters with retention of
PK data, when compared with simultaneous PKPD modelling. However, approx-
imately 25% of computation time was gained by using the sequential method with
ﬁxed individual PK parameter EBEs and omission of PK data in the PD-VD
parameter estimation step. Computation time was not directly compared between
FOCEI and SAEM because different systems (parallel GRID for NONMEM VI and
desktop for MONOLIX) were used. Also much time was wasted with FOCEI runs
that did not terminate successfully. Due to the high failure rate and the long
computation times, it was not practical to perform parameter estimation with FOCEI
using the same hardware system as was used for SAEM.
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123Though the objective of the current analysis was not to directly compare
parameter estimates from SAEM with previous FOCEI analyses, the consistency of
the parameter estimate for IC50 provided conﬁdence in the use of SAEM for this
PKPD-VD model.
In conclusion, the current analyses demonstrated that the SAEM algorithm in
MONOLIX is useful for ﬁtting complex mechanistic models requiring multiple
differential equations. The SAEM algorithm allowed simultaneous estimation of
PKPD and VD parameters, as well as investigation of different model sub-
components during the model building process. This was not possible with the
FOCEI method (implemented in NONMEM version VI and below).
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